Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Abstract:

:High dosage busulfan (1 mg/kg orally every 6 hours x 16 doses) is frequently used in preparative regimens for haemopoietic stem cell transplantation (HSCT). Busulfan is well absorbed after oral administration, exhibits low protein binding and is metabolised through conjugation with glutathione to form a thiophenium ion. At a given dose, there is considerable variability in the systemic exposure of busulfan, typically expressed as area under the plasma concentration-time curve (AUC) or average concentration at steady state (Css). Relative to that in adolescents and adults, patients less than 4 years of age have an increased apparent oral clearance (CL/F) of busulfan and a higher conjugation rate of busulfan with glutathione in the enterocyte. Several investigators have identified relationships between busulfan Css and outcome in patients undergoing HSCT. Busulfan concentration-response relationships are regimen-, age- and disease-dependent. The busulfan/cyclophosphamide (BU/CY) regimen is the only regimen for which substantial concentration-outcome data exist. Generally, the risk of hepatic veno-occlusive disease is increased with busulfan Css > 900 microg/L. The impact of busulfan Css on veno-occlusive disease may be influenced by the age of the patient and the dose of cyclophosphamide. Lower rates of relapse in chronic myelogenous leukaemia occur in patients with a busulfan Css > 917 microg/L without an increased risk of toxicity. Busulfan Css is also related to the engraftment rate in children, and escalating busulfan doses to achieve a target Css > 600 microg/L improves graft retention. Therapeutic drug monitoring of busulfan should be performed to maximise the likelihood of engraftment and minimise the risk of toxicity and relapse in HSCT patients receiving the BU/CY preparative regimen.

journal_name

Clin Pharmacokinet

authors

McCune JS,Gibbs JP,Slattery JT

doi

10.2165/00003088-200039020-00005

keywords:

subject

Has Abstract

pub_date

2000-08-01 00:00:00

pages

155-65

issue

2

eissn

0312-5963

issn

1179-1926

journal_volume

39

pub_type

杂志文章,评审
  • Etodolac clinical pharmacokinetics.

    abstract::Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. I...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199426040-00003

    authors: Brocks DR,Jamali F

    更新日期:1994-04-01 00:00:00

  • Clinical pharmacokinetics of ketoprofen and its enantiomers.

    abstract::Ketoprofen, a potent nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class, has been used clinically for over 15 years in Europe, and has recently been introduced in the United States. Although it possesses a chiral centre, with only the S-enantiomer possessing beneficial pharmacological activi...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199019030-00004

    authors: Jamali F,Brocks DR

    更新日期:1990-09-01 00:00:00

  • Pharmacokinetic optimisation of asthma treatment.

    abstract::Asthma is generally managed with bronchodilator therapy and/or anti-inflammatory drugs. Guidelines now advocate selection of drugs and pharmaceutical formulations (long-acting vs short-acting, inhaled vs systemic) on the basis of disease severity. Theophylline has a narrow therapeutic margin. Clearance is highly varia...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199426050-00006

    authors: Taburet AM,Schmit B

    更新日期:1994-05-01 00:00:00

  • Drug interactions with cisapride: clinical implications.

    abstract::Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-200039010-00004

    authors: Michalets EL,Williams CR

    更新日期:2000-07-01 00:00:00

  • Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

    abstract::Thienopyridines are inactive prodrugs that are converted in vivo to active metabolites, which irreversibly bind to and inactivate platelet P2Y(12) receptors, and inhibit platelet activation and aggregation. Prasugrel is a third-generation thienopyridine, recently approved for prevention of thrombotic cardiovascular co...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/11537820-000000000-00000

    authors: Small DS,Farid NA,Payne CD,Konkoy CS,Jakubowski JA,Winters KJ,Salazar DE

    更新日期:2010-12-01 00:00:00

  • All half-lives are wrong, but some half-lives are useful.

    abstract::The half-life of a drug, which expresses a change in concentration in units of time, is perhaps the most easily understood pharmacokinetic parameter and provides a succinct description of many concentration-time profiles. The calculation of a half-life implies a linear, first-order, time-invariant process. No drug per...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-200140040-00001

    authors: Wright JG,Boddy AV

    更新日期:2001-01-01 00:00:00

  • Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

    abstract::Since 1989 there has been an exponential introduction of new antiepileptic drugs (AEDs) into clinical practice and these include eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine (ezogabine), rufinamide, stiripentol, tiagabine, top...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/s40262-013-0087-0

    authors: Patsalos PN

    更新日期:2013-11-01 00:00:00

  • Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

    abstract::Rational pharmacotherapy is dependent upon an understanding of the clinical pharmacokinetic and pharmacodynamic properties of the drugs employed. Although the available data on drug biodisposition and action in the neonate have increased considerably in the last few years, pharmacokinetic-pharmacodynamic interactions ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198814040-00001

    authors: Besunder JB,Reed MD,Blumer JL

    更新日期:1988-04-01 00:00:00

  • Pharmacokinetics of anticancer drugs in children.

    abstract::Interpatient pharmacokinetic variability normally observed in adults is often of even greater magnitude in paediatric patients because of age-related maturation of physiological processes responsible for drug disposition. Several antineoplastic agents have shown age-related changes, including alterations in volume of ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198712030-00002

    authors: Crom WR,Glynn-Barnhart AM,Rodman JH,Teresi ME,Kavanagh RE,Christensen ML,Relling MV,Evans WE

    更新日期:1987-03-01 00:00:00

  • Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

    abstract::The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the current knowledge regarding the effects of diabetes on these properties remains unclear. Nevertheless, it has been observed ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/11631900-000000000-00000

    authors: Dostalek M,Akhlaghi F,Puzanovova M

    更新日期:2012-08-01 00:00:00

  • Salivary antipyrine half-life during injectable progestagen contraception.

    abstract::Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-198611020-00007

    authors: Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

    更新日期:1986-03-01 00:00:00

  • Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients.

    abstract::A pharmacokinetic study of alpha 1-antitrypsin (ATT) was performed in 2 groups of homozygous PiZ-deficient patients (treated and untreated) and 1 group of healthy volunteers. The distribution of the 131I-labelled protein corresponds to a 3-compartment model. The intravenously administered protein diffused quickly to t...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-199223020-00007

    authors: Constans J,Carles P,Boneu A,Arnaud J,Tufenkji AE,Pujazon MC,Tavera C

    更新日期:1992-08-01 00:00:00

  • Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

    abstract::Beta-adrenoceptor antagonists are among the most commonly prescribed classes of drugs. They are indicated for the treatment of diseases such as hypertension and angina pectoris, in which long term therapy is often required. Since many beta-adrenoceptor antagonists have short plasma elimination half-lives, divided dail...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198713010-00003

    authors: Nace GS,Wood AJ

    更新日期:1987-07-01 00:00:00

  • Models for placental transfer studies of drugs.

    abstract::Pregnancy is a specific dynamic state, and the potential usefulness of caring for a disorder in the fetus or the mother is now well established. Previously, pregnant women have been excluded from clinical trials, therefore only a few studies concerning evaluation of the pregestational metabolism or transplacental tran...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199528020-00006

    authors: Bourget P,Roulot C,Fernandez H

    更新日期:1995-02-01 00:00:00

  • The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding.

    abstract::The relative bioavailability of a single oral dose of temafloxacin given with and without enteral feeding was determined in 18 healthy male volunteers in a randomised crossover study. Subjects were administered 600mg of temafloxacin orally as an intact tablet, or a crushed tablet suspended in water administered throug...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003088-199200221-00008

    authors: Lubowski TJ,Nightingale CH,Sweeney K,Quintiliani R

    更新日期:1992-01-01 00:00:00

  • Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.

    abstract:BACKGROUND AND OBJECTIVE:Genetic polymorphisms of cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associate...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40262-012-0009-6

    authors: Ichimura Y,Takahashi H,Lee MT,Shiomi M,Mihara K,Morita T,Chen YT,Echizen H

    更新日期:2012-12-01 00:00:00

  • Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.

    abstract:BACKGROUND AND OBJECTIVES:This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS:Samples for pharmacokinetic anal...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40262-016-0410-7

    authors: Overgaard RV,Petri KC,Jacobsen LV,Jensen CB

    更新日期:2016-11-01 00:00:00

  • Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.

    abstract::The pharmacokinetics of grepafloxacin in healthy male subjects following single oral administration of doses ranging from 200 to 1200 mg, and following repeated oral administration of 400 and 800 mg doses are reported. Plasma levels of grepafloxacin reached a peak within 2 hours (on average) following drug administrat...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003088-199700331-00003

    authors: Efthymiopoulos C,Bramer SL,Maroli A

    更新日期:1997-01-01 00:00:00

  • Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.

    abstract::Telithromycin is the first ketolide, which is a new class of antibacterial agents related to the macrolides that have structural modifications permitting dual binding to bacterial ribosomal RNA so that activity is retained against Streptococcus pneumoniae with macrolide-lincosamide-streptogramin(B) resistance. Clinica...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-200544090-00003

    authors: Shi J,Montay G,Bhargava VO

    更新日期:2005-01-01 00:00:00

  • Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

    abstract:BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003088-200544120-00011

    authors: Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

    更新日期:2005-01-01 00:00:00

  • Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

    abstract::All of the commonly used anticonvulsants drugs, except possibly primidone, are cleared from the human body mainly by metabolism. The metabolites of phenytoin, phenobarbital and ethosuximide have so far not been shown to possess significant pharmacological activity. However, carbamazepine-10,11-epoxide, derived from ca...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199121010-00003

    authors: Eadie MJ

    更新日期:1991-07-01 00:00:00

  • Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

    abstract::The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19), respectively. CYP2D6 is involved in the stereospecific metabolism of several important groups of drugs, for example antiarrhythmics, antidepressants and ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199529030-00005

    authors: Bertilsson L

    更新日期:1995-09-01 00:00:00

  • Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.

    abstract:BACKGROUND AND OBJECTIVE:Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose-SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s40262-016-0444-x

    authors: Kim E,Howes OD,Kim BH,Chon MW,Seo S,Turkheimer FE,Lee JS,Lee YS,Kwon JS

    更新日期:2017-04-01 00:00:00

  • Clinical pharmacokinetics of lignocaine.

    abstract::Lignocaine is widely used as a local anaesthetic and antiarrhythmic drug. It is commonly administered to patients with acute myocardial infarction as prophylaxis for ventricular fibrillation, although its efficacy in preventing primary ventricular fibrillation is still debated. Toxicity, sometimes with serious clinica...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-197803030-00001

    authors: Benowitz NL,Meister W

    更新日期:1978-05-01 00:00:00

  • Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

    abstract::The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment. Systemic exposure to the drugs or their main metabolites was determined dur...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s40262-016-0431-2

    authors: Lévi F,Karaboué A,Etienne-Grimaldi MC,Paintaud G,Focan C,Innominato P,Bouchahda M,Milano G,Chatelut E

    更新日期:2017-02-01 00:00:00

  • Sex-related differences in drug disposition in man.

    abstract::Sex-related differences in the disposition of some analgesics, anxiolytics and hypnotics have recently been reported. With certain benzodiazepines, sex has been shown to be a more important determinant of variability in drug disposition than age, while with other benzodiazepines an age-related decline in clearance was...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198409030-00001

    authors: Wilson K

    更新日期:1984-05-01 00:00:00

  • The efficiency concept in pharmacodynamics.

    abstract::The classic approach to describe the pharmacological response to a drug is to analyse its concentration-effect relationship, using a variety of possible models such as maximum effect (Emax) models or sigmoid Emax models. The aim of this review is to discuss an alternative way of describing the pharmacological effect i...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199936050-00005

    authors: Alván G,Paintaud G,Wakelkamp M

    更新日期:1999-05-01 00:00:00

  • Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers.

    abstract:OBJECTIVE:To assess the dose proportionality of lacidipine after single and repeated oral doses, and to obtain new information on the pharmacokinetics of the compound since improvement of the plasma assay method. DESIGN:Open, randomised, four-way cross-over trial. PARTICIPANTS:24 healthy male and female volunteers, a...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003088-200342010-00004

    authors: Da Ros L,Squassante L,Milleri S

    更新日期:2003-01-01 00:00:00

  • Clinical implications of indapamide sustained release 1.5 mg in hypertension.

    abstract::Recent international guidelines on the detection, clinical assessment and management of patients with hypertension have highlighted a number of themes that should be incorporated into routine clinical practice. First, although antihypertensive therapy is having a major impact on reducing the incidence of coronary hear...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199937001-00004

    authors: Donnelly R

    更新日期:1999-01-01 00:00:00

  • A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.

    abstract::Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/s40262-017-0546-0

    authors: Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

    更新日期:2017-11-01 00:00:00